CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 9, 2013
Result type: Reports
Project Number: SR0331-000
Product Line: Reimbursement Review

Generic Name: Lurasidone

Brand Name: Latuda

Manufacturer: Sunovion Pharmaceuticals Inc.

Therapeutic Area: Schizophrenia

Indications: Schizophrenia

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: December 20, 2013

Recommendation Type: List with criteria/condition